SCHEMBL4124736

SCHEMBL4124736

CC(=O)Nc1nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc2c1C(=O)NN(C)c1ccccn1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.34
TDP1 Q9NUW8 2/20 0.33
LIMK1 P53667 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
NR3C1 P04150 1/20 0.32
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CNR2 P34972 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
NTRK1 P04629 1/20 0.32
PDE4B Q07343 2/20 0.31
PDE4D Q08499 2/20 0.31
PDE4A P27815 1/20 0.31
PDE4C Q08493 1/20 0.31
DEGS1 O15121 1/20 0.31
MC4R P32245 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124748 0.89 CNR1 (0.34) CNR1TDP1MAPTSMN1; SMN2
SCHEMBL4121879 0.86 HTT (0.36) CNR1TDP1KDM4EALDH1A1HTT
SCHEMBL2086773 0.86 F10 (0.34) CNR1TDP1NR3C1MAPTSMN1; SMN2
SCHEMBL2085682 0.86 CNR1 (0.33) CNR1TDP1NR3C1MAPTSMN1; SMN2
SCHEMBL4112770 0.85 NPC1 (0.33) CNR1TDP1NR3C1MAPTSMN1; SMN2
SCHEMBL2085825 0.85 MAPT (0.32) CNR1TDP1MAPTSMN1; SMN2CNR2
SCHEMBL8219745 0.83 CNR2 (0.34) CNR1TDP1LIMK1KDM4EALDH1A1
SCHEMBL4121225 0.82 JAK2 (0.36) TDP1KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL2084584 0.82 MALT1 (0.32) CNR1MAPTSMN1; SMN2
SCHEMBL4114463 0.80 NR3C1 (0.37) NR3C1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US claimed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD CNR1 285/4885TDP1 1059/4885LIMK1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.